Anticonvulsants and congenital malformations

Area of Science:

• Obstetrics and Gynecology
• Pediatrics
• Clinical Pharmacology

Background:

• Previous research suggests a higher incidence of congenital anomalies in infants of epileptic mothers on anticonvulsant therapy.
• Epilepsy treatment during pregnancy necessitates careful consideration of potential risks to fetal development.

Purpose of the Study:

• To investigate the association between anticonvulsant drug exposure in the first trimester of pregnancy and the risk of major congenital anomalies in liveborn infants.
• To compare anomaly rates in infants of epileptic mothers treated with anticonvulsants versus those with epilepsy not on medication and non-epileptic controls.

Main Methods:

• A retrospective cohort study using the General Practice Research Database.
• Inclusion criteria: women delivering liveborn infants between January 1988 and March 1993.
• Exposure groups: 1) epileptic mothers treated with anticonvulsants during the first trimester, 2) epileptic mothers not treated with anticonvulsants, and 3) matched non-epileptic controls (2:1 ratio).

Main Results:

• 297 women treated with anticonvulsants had 10 infants (3.4%) with major anomalies.
• 594 nonexposed women had 6 infants (1.0%) with major anomalies.
• The relative risk (RR) of major anomalies in the exposed group was 3.3 (95% CI 1.2-9.2).

Conclusions:

• Infants of women with epilepsy treated with anticonvulsants during the first trimester have a significantly increased risk of major congenital anomalies.
• These findings underscore the need for risk-benefit assessment in managing epilepsy during pregnancy.
• Further research may explore specific anticonvulsant risks and alternative treatment strategies.